Cytokinetics, Incorporated CYTK
64.66
(1.00)
(1.52%)
as of 25 Sep
- Market cap
- $9.0B
- P/E
- 0.0×
Follow CYTK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
166.28 | 76.78 | 86.68 | 75.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(70.40) | (55.86) | (53.50) | (61.34) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
166.01 | 80.04 | 89.80 | 77.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(20.22) | (16.17) | (15.50) | (15.52) | |
EV/FCF |
(19.34) | (15.43) | (14.78) | (14.82) | |
Quick Ratio |
6.56 | 4.14 | 4.45 | 6.78 | |
Current Ratio |
6.66 | 4.21 | 4.53 | 6.88 | |
Net Debt/EBITDA |
0.11 | (1.91) | (1.57) | (0.75) | |
Debt/Assets |
59.60% | 91.29% | 81.23% | 75.61% | |
Debt/Equity |
(6.61) | (1.41) | (1.75) | (2.08) | |
Asset Turnover |
0.04 | 0.08 | 0.06 | 0.06 | |
Operating CF/Net income |
0.80 | 0.71 | 0.78 | 0.35 | |
Capex/Depreciation |
(1.19) | (1.76) | (1.97) | (3.49) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
341.70% | 493.54% | 610.49% | 5,125.67% | |
Selling, General and Administrative Expense of Revenue |
364.72% | 541.96% | 516.60% | 3,587.71% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
124.76% | 157.03% | 171.82% | 1,585.54% | |
Graham Net Nets |
(0.08) | (0.16) | (0.15) | (0.15) | |
Graham Number |
14.61 | 32.12 | 28.41 | 24.79 | |
Earnings Yield |
(8.48%) | (10.38%) | (10.28%) | (11.44%) | |
Free Cash Flow Yield |
(5.16%) | (6.76%) | (7.01%) | (6.88%) | |
Revenue per Share |
0.22 | 0.16 | 0.15 | 0.02 | |
Operating CF per Share |
(1.21) | (1.18) | (1.19) | (0.90) | |
Capex per Share |
(0.03) | (0.05) | (0.05) | (0.08) | |
Free Cash Flow per Share |
(1.24) | (1.23) | (1.23) | (0.97) | |
Cash per Share |
8.83 | 6.64 | 7.35 | 8.02 | |
Shareholders Equity per Share |
(1.31) | (6.71) | (5.49) | (4.34) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.31) | (6.71) | (5.49) | (4.34) | |
Free Cash Flow |
(164.17) | (151.39) | (148.29) | (116.86) | |
Working Capital |
1,027.06 | 640.28 | 714.52 | 835.21 | |
Capital Expenditures |
(4.33) | (5.93) | (5.64) | (9.35) | |
Net Current Asset Value |
(889.55) | (1,260.58) | (1,167.19) | (980.33) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.15 | 0.31 | 0.32 | 4.83 | |
Net Profit Margin |
(694.39%) | (1,064.48%) | (1,030.87%) | (15,814.98%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.42 | 4.42 | 17.21 | 1.03 | |
Average Payables |
18.37 | 19.33 | 21.35 | 16.83 | |
Average Assets |
1,575.09 | 1,268.76 | 1,413.11 | 1,436.31 | |
Average Common Equity |
(271.10) | (546.49) | (397.50) | (267.52) |
Columns are period end dates